These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
313 related articles for article (PubMed ID: 33899154)
1. Nusinersen treatment in adult patients with spinal muscular atrophy: a safety analysis of laboratory parameters. Stolte B; Nonnemacher M; Kizina K; Bolz S; Totzeck A; Thimm A; Wagner B; Deuschl C; Kleinschnitz C; Hagenacker T J Neurol; 2021 Dec; 268(12):4667-4679. PubMed ID: 33899154 [TBL] [Abstract][Full Text] [Related]
2. Safety analysis of laboratory parameters in paediatric patients with spinal muscular atrophy treated with nusinersen. Zhu X; Li H; Hu C; Wu M; Zhou S; Wang Y; Li W BMC Pediatr; 2024 Jul; 24(1):474. PubMed ID: 39054521 [TBL] [Abstract][Full Text] [Related]
3. Inflammatory markers in cerebrospinal fluid of paediatric spinal muscular atrophy patients receiving nusinersen treatment. Scheijmans FEV; Cuppen I; Zwartkruis MM; Signoria I; van Ekris C; Asselman F; Wadman RI; Knol EF; van der Pol WL; Groen EJN Eur J Paediatr Neurol; 2023 Jan; 42():34-41. PubMed ID: 36525882 [TBL] [Abstract][Full Text] [Related]
4. Efficacy of nusinersen in type 1, 2 and 3 spinal muscular atrophy: Real world data from Hungarian patients. Szabó L; Gergely A; Jakus R; Fogarasi A; Grosz Z; Molnár MJ; Andor I; Schulcz O; Goschler Á; Medveczky E; Czövek D; Herczegfalvi Á Eur J Paediatr Neurol; 2020 Jul; 27():37-42. PubMed ID: 32456992 [TBL] [Abstract][Full Text] [Related]
5. Nusinersen for Spinal Muscular Atrophy in the United States: Findings From a Retrospective Claims Database Analysis. Gauthier-Loiselle M; Cloutier M; Toro W; Patel A; Shi S; Davidson M; Bischof M; LaMarca N; Dabbous O Adv Ther; 2021 Dec; 38(12):5809-5828. PubMed ID: 34713391 [TBL] [Abstract][Full Text] [Related]
6. Adherence and Persistence to Nusinersen for Spinal Muscular Atrophy: A US Claims-Based Analysis. Fox D; To TM; Seetasith A; Patel AM; Iannaccone ST Adv Ther; 2023 Mar; 40(3):903-919. PubMed ID: 36534265 [TBL] [Abstract][Full Text] [Related]
7. Treatment expectations and patient-reported outcomes of nusinersen therapy in adult spinal muscular atrophy. Osmanovic A; Ranxha G; Kumpe M; Müschen L; Binz C; Wiehler F; Paracka L; Körner S; Kollewe K; Petri S; Schreiber-Katz O J Neurol; 2020 Aug; 267(8):2398-2407. PubMed ID: 32361837 [TBL] [Abstract][Full Text] [Related]
8. Safety and Treatment Effects of Nusinersen in Longstanding Adult 5q-SMA Type 3 - A Prospective Observational Study. Walter MC; Wenninger S; Thiele S; Stauber J; Hiebeler M; Greckl E; Stahl K; Pechmann A; Lochmüller H; Kirschner J; Schoser B J Neuromuscul Dis; 2019; 6(4):453-465. PubMed ID: 31594243 [TBL] [Abstract][Full Text] [Related]
9. Cerebrospinal Fluid and Clinical Profiles in Adult Type 2-3 Spinal Muscular Atrophy Patients Treated with Nusinersen: An 18-Month Single-Centre Experience. Milella G; Introna A; D'Errico E; Fraddosio A; Scaglione G; Morea A; Ucci M; Ruggieri M; Mastrapasqua M; Megna M; Puntillo F; Simone IL Clin Drug Investig; 2021 Sep; 41(9):775-784. PubMed ID: 34389971 [TBL] [Abstract][Full Text] [Related]
10. Nusinersen: antisense oligonucleotide to increase SMN protein production in spinal muscular atrophy. Paton DM Drugs Today (Barc); 2017 Jun; 53(6):327-337. PubMed ID: 28799578 [TBL] [Abstract][Full Text] [Related]
11. Stability of serial platelet and urine protein measurements in patients receiving nusinersen for spinal muscular atrophy. Nagarajan EK; Özütemiz C; Rubin N; Nascene DR Muscle Nerve; 2022 Jul; 66(1):76-79. PubMed ID: 35466424 [TBL] [Abstract][Full Text] [Related]
12. Nusinersen treatment significantly improves hand grip strength, hand motor function and MRC sum scores in adult patients with spinal muscular atrophy types 3 and 4. De Wel B; Goosens V; Sobota A; Van Camp E; Geukens E; Van Kerschaver G; Jagut M; Claes K; Claeys KG J Neurol; 2021 Mar; 268(3):923-935. PubMed ID: 32935160 [TBL] [Abstract][Full Text] [Related]
13. Nusinersen treatment of Spinal Muscular Atrophy Type 1 - results of expanded access programme in Poland. Modrzejewska S; Kotulska K; Kopyta I; Grędowska E; Emich-Widera E; Tomaszek K; Paprocka J; Chmielewski D; Pilch J; Pietruszewski J; Lemska A; Zawadzka M; Mazurkiewicz-Bełdzińska M Neurol Neurochir Pol; 2021; 55(3):289-294. PubMed ID: 33565602 [TBL] [Abstract][Full Text] [Related]
14. Real-World Data from Nusinersen Treatment for Patients with Later-Onset Spinal Muscular Atrophy: A Single Center Experience. Mendonça RH; Polido GJ; Matsui C; Silva AMS; Solla DJF; Reed UC; Zanoteli E J Neuromuscul Dis; 2021; 8(1):101-108. PubMed ID: 33074187 [TBL] [Abstract][Full Text] [Related]